wildbird1 wrote: For information purpose....
Here is what I consider TLT management two best achievements since day one.
Number 1 best achievement.
- Definitively teaming up with that first-class genious Dr Sherri McFarland.
She didn't stop with creating TLD-1433.
No! She kept on searching for better PDC, as stipulated in this 2017 link...
Theralase® Researcher Discovers Super Potent Anti-Cancer Drugs – Theralase Technologies '' Theralase researcher(Dr McFarland) discovers new super potent anti-cancer drug,
10 billion time more potent in killing cancer cells than other tested PDC... and according to Dr McFarland it has a very low toxicity level.
Two questions.
Question 1-What would happen if you combine this new super PDC with Metformin, a safe generic(free for commercial use) diabetic drug that can activate PDC anywhere in the body without the need for light?
Question 2-How much$ would a Big Pharma be willing to pay for such a powerful PDC compound.
Note: Why haven't we heard more about that super PDC compound?
It takes many years of testing and a lot of money to prove that a new compound is safe for testing on human.
As we speak TLT management is giving priority to the FDA BTD approval of TLD-1433.
But once TLD-1433 get BTD approval and a Big Pharma joint-venture $deal,
WATCH OUT. Number 2 best achievement.
I love repeating this next one(and will continue to do so).
-The unsurpassed data and Duration Of Response of Ruvidar, that brought on the backing of the Scientific Community, as stipulated in Eoganacht 2 articles.
''
Today's TLD-1433 shout out'' (1 and 2). The backing of the Scientific Community is a very trustworthy signal indicating that the FDA approval of TLD-1433 is just a question of time.
$Note: A Big Pharma negotiating a JV deal with TLT will certainly know about Dr McFarland super PDC, and it could increase big time the $value of a Big Pharma deal.
To new investors, buy and hold, because after the FDA approval of TLD-1433, things could evolve much faster. I love TLT management.
And I love my TLT shares.